全球知识产权每日洞察 — 2026-05-26

Context:

Huawei has one of the most successful licensing businesses in the world, revealing a few months ago that, in 2024 alone, it accrued $630 million in patent licensing revenue (which is high, given it is also a high-volume implementer and therefore many of its deals are cross-licensing agreements). It is also a big fan of pools, with Strategic Planning & Key Projects Department head Emil Zhang explaining to

ip fray

last month why diversifying its licensing strategy has been so crucial for the company (

April 20, 2026

To Read The Full Story

Sign In

Continue reading your article with a Membership

Contact us

Context:

Geotab filed a petition for inter partes review (IPR) at the United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) in April 2025, challenging the validity of multiple claims in

U.S. Patent No. 8,810,458

(“Handheld device with two antennas, and method of enhancing the isolation between the antennas”). Coke Morgan Stewart, Acting (now Deputy) USPTO Director, issued a discretionary denial of the IPR petition in September 2025, at least on the partial basis that patentee Fractus possessed “settled expectations” due to the ‘458 patent’s 11-plus years in force. Seeking another route to invalidation, Geotab submitted a request for ex parte reexamination of the ‘458 patent in February 2026.

To Read The Full Story

Malta-based

Adalvo

is a B2B pharmaceutical company that licenses its products and IP to generic partners across the industry, including, for example, a portfolio of products that focuses on oncology, women’s health, cardiovascular, and the central nervous system. The company is a sort of “middleman” and also offers IP strategy guidance to its partners.

Steering the company’s IP department out of Barcelona is Toni Santamaria. His team of seven is spread across Europe and India and manages a portfolio of about 40 active patents. Mr. Santamaria, who has been at Adalvo since August 2021, was appointed Chief IP Officer last year.

In an interview with